¡·¤å¡þ¶ÀÄÉùÜÃÄ®v
¯f¤H°Ý¡G¦pªG±µºØ¹L±aª¬¯p¯l¬Ì]¡]¥ñ±a¯l, Zostavax¡^¡AÁÙ¥i¥H¦A¥´·sªº±aª¬¯p¯l¬Ì]¡]ªY«g¯l, Shingrix¡^¶Ü¡H»Ýn¶¡¹j¦h¤[¡H
ÃÄ®vµª¡G¥i¥H¡C¦Ü¤Ö¶¡¹j2Ó¤ë¡C
ÃÄ®v¸Óª¾¹Dªº¨Æ
±aª¬¯p¯l©Î«UºÙ¥Ö³D¡A¬O¤@ºØ·|³y¦¨±j¯P¯kµhªº¥Ö½§¯l¡A³q±`µo¥Í¦bÁy³¡©Î¨Å骺¤@°¼¡C¥¦¥Ñ¤ôµk-±aª¬¯p¯l¯f¬r¡]varicella-zoster
virus, VZV¡^¤Þ°_¡A³oºØ¯f¬r¤]¬O¤Þ°_¤ôµkªºì¦]¡C¥ô¦ó±o¹L¤ôµkªº¤H³£¥i¯àµo¥Í±aª¬¯p¯l¡A¦]¬°VZV¦b¤ôµk±d´_«á¤´µM¯d¦bÅ餺¡CVZV¦b¦~ªø¦¨¤H¡B§K¬Ì¥\¯à¤£¥þªº¯f¤H¡A¥H¤ÎªA¥Î§í¨î§K¬Ì¨t²ÎÃĪ«ªº¤H¸s¤¤®e©ö«·s¬¡¤Æ¡A¾ÉP±aª¬¯p¯l¡C±µºØ¬Ì]¬O¹w¨¾±aª¬¯p¯lªº³Ì¨Î¤è¦¡¡C
·s´Úªº±aª¬¯p¯l¬Ì]¡]ªY«g¯l, Shingrix¡^»Ýn¬I¥´¨â¾¯¡]²Ä0, 2-6Ó¤ë¡^¡A¬°¤@ºØ«D¬¡©Ê°ò¦]«²Õ¬Ì]¡]Recombinant
Zoster Vaccine, RZV¡^¡A¦b¤@¶µphase
III¡B¦h¤¤¤ßªº¬ã¨s¦¬¯Ç¶W¹L30,000¤H¡A¥HÀH¾÷1¡G1¤À°tµ¹¤©¬Ì]©ÎªÌ¦w¼¢¾¯¡A¨Ã°õ¦æ¨â¶¥¬qµû¦ô®Ä¤O»P¦w¥þ©Ê¡Cµ²ªGÅã¥Ü¡A¹w¨¾±aª¬¯p¯lªº®ÄªG¦b50¦Ü59·³¬°96.6%¡]95%
CI= 89.6-99.3¡^¡B60¦Ü69·³¬°97.4%¡]95% CI = 90.1-99.7¡^¡B70·³¤Î¥H¤W¬°91.3%¡]95% CI
= 86.8-94.5¡^¡C¹w¨¾±aª¬¯p¯l«á¯«¸gµhªº®ÄªG¦b50·³¤Î¥H¤W¬°91.2%¡]95% CI =
75.9-97.7¡^¡A70·³¤Î¥H¤WªÌ¤¤¬°88.8%¡]95% CI =
68.7-97.1¡^¡C³Ì±`¨£ªº°Æ§@¥Î¬°¯kµh¡]78%¡^¡B¦Ù¦×µh¡]45%¡^©M¯h³Ò¡]45%¡^¡C
´ڪº±aª¬¯p¯l¬Ì]¡]¥ñ±a¯l, Zostavax¡^¡A¬O¤@ºØ¬¡©Ê´î¬r¬Ì]¡]Zoster Vaccine Live ,ZVL¡^¡A¥u»Ýn¥´¤@¾¯¡C¦b¨â¶µÀH¾÷¹ï·Ó¸ÕÅç»P¤C¶µÆ[¹î©Ê¬ã¨s¤¤¡A¨ä¹w¨¾±aª¬¯p¯lªº®ÄªG¦b50¦Ü59·³¬°70%¡]95%
CI = 54-81¡^¡B60¦Ü69·³¬°64%¡]95% CI = 56-71¡^¡B70·³¤Î¥H¤W¬°38%¡]95% CI =
25-48¡^¡A¥B®Ä¤OÀHµÛ±µºØ®É¶¡¹L±o¶V¤[°§C¶V¦h¡C¹w¨¾±aª¬¯p¯l«á¯«¸gµhªº®ÄªG¦b60¦Ü69·³65.7%¡]95% CI =
20.4-86.7¡^¡B70·³¤Î¥H¤W¬°66.8%¡]95% CI = 43.3-81.3¡^¡C
¦]Shingrix¦b¹w¨¾±aª¬¯p¯lªº®Ä¤O©úÅãÀu©ó Zostavax¡A¥Ø«e¬ü°ê¬Ì]±µºØ¿Ô¸ß©eû·|¡]Advisory Committee on
Immunization Practices, ACIP¡^«ØijY¥¼¥´¹L¥ô¦ó±aª¬¯p¯l¬Ì]¡AÀu¥ý¿ï¾Ü¬I¥´Shingrix¡A¦pªG¤w¸g¥´¹LZostavax¡A¤´«Øij¦Aª`®gShingrix¡A¦Ü¤Ö»Ý¶¡¹j¨âÓ¤ë¡C
°Ñ¦Ò¸ê®Æ¡G
1.Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted
Recombinant Zoster Vaccine Confers Long-Term Protection Against
Herpes Zoster¡G Interim Results of an Extension Study of the Pivotal
Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis.
2022;74¡]8¡^¡G1459-1467. doi¡G10.1093/cid/ciab629
2.Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and
tolerability of herpes zoster vaccine in persons aged 50-59 years.
Clin Infect Dis 2012;54¡G922-8
3.Oxman MN, Levin MJ, Johnson GR, et al. ; Shingles Prevention Study
Group. A vaccine to prevent herpes zoster and postherpetic neuralgia
in older adults. N Engl J Med 2005;352¡G2271-84.
4.CDC- Frequently Asked Questions About Shingrix. https¡G//www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/faqs.html
¡@
¡]¥»¤å§@ªÌ¬°©_¬üÂåÀø°]¹Îªk¤H©_¬üÂå°|Á{§ÉÃÄ®v /¤¤°êÂåÃĤj¾ÇÃľǨt¾Ç¤h¡^
¡@
¡@
¡@
¡@
¡@
¡@
¦^º¶ |